Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention

Cardiovascular Revascularization Medicine

Volumn 10, Issue 1, 2009, Pages 36-44

  Tan, Victoria P ^a   Yan, Bryan P ^b,c,d   Kiernan, Thomas J ^e   Ajani, Andrew E ^a,d,f  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clopidogrel; Drug eluting stent; Gastrointestinal bleeding; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; SCH 530348; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; BARE METAL STENT; BLOOD TRANSFUSION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DRUG ELUTING STENT; DRUG MEGADOSE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HELICOBACTER INFECTION; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; UPPER GASTROINTESTINAL BLEEDING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFECTIVE AGENTS; ASPIRIN; BLOOD TRANSFUSION; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER PYLORI; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 58249130322     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2008.11.001     Document Type: Review

References (53)

1. Cutlip D.E., Baim D.S., Ho K.K., Popma J.J., Lansky A.J., Cohen D.J., Carrozza J.P., Chauhan M.S., Rodriguez O., and Kuntz R.E. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 15 (2001) 1967-1971
2. Wang F., Stouffer G.A., Waxman S., and Uretsky B.F. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 55 2 (2002) 142-147
3. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., and Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (2005) 2126-2130
4. Holmes D.R., Kereiakes D.J., Laskey W.K., Colombo A., Ellis S.G., Henry T.D., Popma J.J., Serruys P.W., Kimura T., Williams D.O., Windecker S., and Krucoff M.W. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 50 2 (2007) 109-118
5. Grines C.L., Bonow R.O., Casey D.E., Gardner T.J., Lockhart P.B., Moliterno D.J., O'Gara P., Whitlow P., American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, American Dental Association, and American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 6 (2007) 813-818
6. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Copland I., Fox K.A., and Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 9281 (2001) 527-533
7. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J., and CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 19 (2002) 2411-2420
8. Waksman R., Ajani A.E., Pinnow E., Cheneau E., Leborgne L., Dieble R., Bui A.B., Satler L.F., Pichard A.D., Kent K.K., and Lindsay J. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106 7 (2002) 776-778
9. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., Peterson E.D., Schulman K.A., and Califf R.M. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 2 (2007) 159-168
10. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 10 (2007) 1009-1019
11. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
12. Smith S.C., Feldman T.E., Hirshfeld J.W., Jacobs A.K., Kern M.J., King S.B., Morrison D.A., O'Neill W.W., Schaff H.V., Whitlow P.L., Williams D.O., Antman E.M., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Hunt S.A., Nishimura R., Ornato J.P., Page R.L., and Riegel B. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
13. Spertus J.A., Kettelkamp R., Vance C., Decker C., Jones P.G., Rumsfeld J.S., Messenger J.C., Khanal S., Peterson E.D., Bach R.G., Krumholz H.M., and Cohen D.J. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
14. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., Fitzgerald D., Hirsh J., Husted S., Kvasnicka J., Montalescot G., García Rodríguez L.A., Verheugt F., Vermylen J., Wallentin L., Priori S.G., Alonso Garcia M.A., Blanc J.J., Budaj A., Cowie M., Dean V., Deckers J., Fernández Burgos E., Lekakis J., Lindahl B., Mazzotta G., Morais J., Oto A., Smiseth O.A., Morais J., Deckers J., Ferreira R., Mazzotta G., Steg P.G., Teixeira F., Wilcox R., and European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 25 2 (2004) 166-181
15. Lai K.C., Lam S.K., Chu K.M., Wong B.C., Hui W.M., Hu W.H., Lau G.K., Wong W.M., Yuen M.F., Chan A.O., Lai C.L., and Wong J. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 26 (2002) 2033-2038
16. CAPRIE Investigators. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 9038 (1996) 1329-1339
17. Ng F.H., Wong S.Y., Chang C.M., Chen W.H., Kng C., Lanas A.I., and Wong B.C. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 18 4 (2003) 443-449
18. Eikelboom J.W., and Hirsh J. Bleeding and management of bleeding. Eur Heart J 8 Suppl. G (2006) G38-G45
19. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
20. Peters R.J., Mehta S.R., Fox K.A., Zhao F., Lewis B.S., Kopecky S.L., Diaz R., Commerford P.J., Valentin V., Yusuf S., and Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 14 (2003) 1682-1687
21. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Flather M.D., Haffner S.M., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Brennan D.M., Fabry-Ribaudo L., Booth J., Topol E.J., and CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 16 (2006) 1706-1717
22. Hermosillo A.J., and Spinler S.A. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?. Ann Pharmacother 42 6 (2008) 790-805
23. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M., and TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 20 (2007) 2001-2015
24. Angiolillo D.J., and Guzman L.A. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 156 2 Suppl (2008) S23-S28
25. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 8 (2006) 774-782
26. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., Mahaffey K.W., Califf R.M., and Harrington R.A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 9 (2005) 1200-1206
27. Twomley K.M., Rao S.V., and Becker R.C. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions. J Thromb Thrombolysis 21 2 (2006) 167-174
28. Rao S.V., Jollis J.G., Harrington R.A., Granger C.B., Newby L.K., Armstrong P.W., Moliterno D.J., Lindblad L., Pieper K., Topol E.J., Stamler J.S., and Califf R.M. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
29. Yang X., Alexander K.P., Chen A.Y., Roe M.T., Brindis R.G., Rao S.V., Gibler W.B., Ohman E.M., Peterson E.D., and CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46 (2005) 1490-1495
30. Hébert P.C., Wells G., Blajchman M.A., Marshall J., Martin C., Pagliarello G., Tweeddale M., Schweitzer I., and Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (1999) 409-417
31. Orford J.L., Fasseas P., Melby S., Burger K., Steinhubl S.R., Holmes D.R., and Berger P.B. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 147 (2004) 463-467
32. Lanas A., Bajador E., Serrano P., Fuentes J., Carreño S., Guardia J., Sanz M., Montoro M., and Sáinz R. Nitrovasodilators, low dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. New Engl J Med 343 (2000) 834-839
33. Ng F.H., Wong B., Wong S.Y., Chen W.H., and Chang C.M. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk - a single-blind, randomized controlled study. Aliment Pharmacol Ther 19 (2004) 359-365
34. Ng F.H., Wong S.Y., Lam K.F., Chang C.M., Lau Y.K., Chu W.M., and Wong B.C. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 103 4 (2008) 865-871
35. Barada K., Karrowni W., Abdallah M., Shamseddeen W., Sharara A.I., and Dakik H.A. Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors. J Clin Gastroenterol 42 4 (2008) 368-372
36. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., and Rupprecht H.J. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364 9431 (2004) 331-337
37. Adang R.P., Vismans J.F., Talmon J.L., Hasman A., Ambergen A.W., and Stockbrugger R.W. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc 42 5 (1995) 390-397
38. Zuccaro G. Management of the adult patient with acute lower gastrointestinal bleeding. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 93 8 (1998) 1202-1208
39. Faust R.J., and Ellison N. American College of Physicians: practice strategies for elective red blood cell transfusion. Ann Intern Med 116 (1992) 403-406
40. Nikolsky E., Aymong E.D., Halkin A., Grines C.L., Cox D.A., Garcia E., Mehran R., Tcheng J.E., Griffin J.J., Guagliumi G., Stuckey T., Turco M., Cohen D.A., Negoita M., Lansky A.J., and Stone G.W. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 44 (2004) 547-553
41. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I., and Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27 (2006) 2667-2674
42. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., Hernández R., Moreno R., Escaned J., Alfonso F., Bañuelos C., Costa M.A., Bass T.A., and Macaya C. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55 (2006) 780-784
43. Knudsen J.B., Bastain W., Sefton C.M., Allen J.G., and Dickinson J.P. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 22 (1992) 579-589
44. Rupprecht H.J., Darius H., Borkowski U., Voigtländer T., Nowak B., Genth S., and Meyer J. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 97 11 (1998) 1046-1052
45. Rockall T.A., Logan R.F., Devlin H.B., and Northfield T.C. Risk assessment after acute upper gastrointestinal hemorrhage. Gut 38 (1996) 316-321
46. Cappell M.S., and Iacovone F.M. Safety and efficacy of esophagogastroduodenoscopy after myocardial infarction. Am J Med 106 (1999) 29-35
47. Sung J.Y., Chung S.C., Low J.M., Cocks R., Ip S.M., Tan P., Leung J.W., Li A.K., and Oh T.E. Systemic absorption of epinephrine after endoscopic submucosal injection in patients with bleeding peptic ulcers. Gastrointest Endosc 39 (1993) 20-22
48. Calvet X., Vergara M., Brullet E., Gisbert J.P., and Campo R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high risk bleeding ulcers. Gastroenterology 126 (2004) 441-450
49. Cappell M.S. Safety and efficacy of colonoscopy after myocardial infarction: an analysis of 100 study patients and 100 control patients at two tertiary cardiac referral hospitals. Gastrointest Endosc 60 (2004) 901-909
50. Hui A.J., Wong R.M., Ching J.Y., Hung L.C., Chung S.C., and Sung J.J. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 59 (2004) 44-48
51. Dacey L.J., Munoz J.J., Johnson E.R., Leavitt B.J., Maloney C.T., Morton J.R., Olmstead E.M., Birkmeyer J.D., O'Connor G.T., and Northern New England Cardiovascular Disease Study Group. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 70 (2000) 1986-1990
52. Rabbat M.G., Bavry A.A., Bhatt D.L., and Ellis S.G. Understanding and minimizing late thrombosis of drug eluting stents. Clev Clinic J Med 74 (2007) 129-136
53. Yan B.P., Gurvitch R., and Ajani A.E. Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation. Cardiovasc Revasc Med 7 3 (2006) 155-158